TROPION-Lung01 Study Design and Baseline demographics slide image

TROPION-Lung01 Study Design and Baseline demographics

Daiichi-Sankyo Dato-DXd (n=360) ICC (n=351) Preferred term, n (%) Any Grade Grade ≥3 Any Grade Grade ≥3 Blood and lymphatic system Anaemia 40 (11) 4 (1) 69 (20) Neutropenia* 39 (11) 4 (1) 149 (42) Eye Dry eye 78 (22) 2 (1) 27 (8) Gastrointestinal Nausea 184 (51) 5 (1) 83 (24) Stomatitis 180 (50) 23 (6) 46 (13) Vomiting 71 (20) 4 (1) 27 (8) Constipation 65 (18) 0 32 (9) TRAES Occurring in ≥15% of Patients and AESIS System Organ Class • • Most TRAEs were grade 1-2 and manageable AESIs Oral mucositis/stomatitis: led to treatment discontinuation in one patient in the Dato-DXd group Ocular events: most were dry eye; one patient discontinued treatment in the Dato-DXd group Adjudicated drug-related ILD:S rate was low; mainly grade 1/2 7 (2) • 108 (31) 0 2 (1) 9 (3) • 2 (1) 0 General Fatigue Skin and subcutaneous Alopecia 85 (24) 6 (2) 64 (18) 7 (2) Adjudicated drug-related ILD Dato-DXd ICC All grades, n (%) 9 (3) 0 131 (36) 0 72 (21) 0 Grade ≥3, n (%) 2 (1)1 0 *Neutropenia includes the PTs neutropenia and neutrophil count decreased. "Oral stomatitis/mucositis events included PTs of aphthous ulcer, dysphagia, glossitis, mouth ulceration, odynophagia, oral mucosal blistering, oral pain, oropharyngeal pain, pharyngeal inflammation, stomattis, tongue ulceration; all grade: 59% with Dato-DXd, 17% with ICC; grade 3: 7% with Dato-DXd, 3% with ICC. #Ophthalmologic assessments were required at screening, and then every 3 cycles from C1D1 and at end of therapy; ocular events included selected PTs from Corneal Disorder SMQ and select relevant PTs from Eye Disorder SOC; all grade: 49% with Dato-DXd, 23% with ICC; grade 3: 1% with Dato-DXd (one patient with dry eye, one patient with punctate kerattis, and one patient with dry eye and ulcerative kerafts), 0% with ICC. $ILD includes events that were adjudicated as ILD and related to use of Dato-DXd or ICC (includes cases of potential ILD/pneumonitis, based on MedDRA v23.0 for the narrow ILD SMQ, selected terms from the broad ILD SMQ, and PTs of respiratory failure and acute respiratory failure). One adjudicated drug-related grade 5 ILD event attributed to disease progression by investigator. ILD, interstitial lung disease; PTs, preferred terms; SMQ, standard MedDRA query; SOC, system organ class. 34
View entire presentation